PL2759595T3 - Kompozycja zawierająca kapsułkowany antagomir - Google Patents

Kompozycja zawierająca kapsułkowany antagomir

Info

Publication number
PL2759595T3
PL2759595T3 PL13305082T PL13305082T PL2759595T3 PL 2759595 T3 PL2759595 T3 PL 2759595T3 PL 13305082 T PL13305082 T PL 13305082T PL 13305082 T PL13305082 T PL 13305082T PL 2759595 T3 PL2759595 T3 PL 2759595T3
Authority
PL
Poland
Prior art keywords
composition
encapsulated antagomir
antagomir
encapsulated
Prior art date
Application number
PL13305082T
Other languages
English (en)
Polish (pl)
Inventor
Miguel-Angel Asin
Eulalia Ferret
Amadeo Perez
Garcia Antonio David Garcia-Dorado
Ignasi Barba Vert
Sinovas Antonio Rodriguez
Neus Bellera Gotarda
Original Assignee
Pierre Fabre Médicament S.A.S.
Fundació Hospital Universitari Vall D'hebron - Institut De Recerca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Médicament S.A.S., Fundació Hospital Universitari Vall D'hebron - Institut De Recerca filed Critical Pierre Fabre Médicament S.A.S.
Publication of PL2759595T3 publication Critical patent/PL2759595T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL13305082T 2013-01-24 2013-01-24 Kompozycja zawierająca kapsułkowany antagomir PL2759595T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13305082.3A EP2759595B1 (en) 2013-01-24 2013-01-24 Composition comprising an encapsulated antagomir

Publications (1)

Publication Number Publication Date
PL2759595T3 true PL2759595T3 (pl) 2017-09-29

Family

ID=47683670

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13305082T PL2759595T3 (pl) 2013-01-24 2013-01-24 Kompozycja zawierająca kapsułkowany antagomir

Country Status (16)

Country Link
US (1) US20150352055A1 (enExample)
EP (2) EP2759595B1 (enExample)
JP (1) JP2016506923A (enExample)
KR (1) KR20160018451A (enExample)
CN (1) CN105229151A (enExample)
AU (1) AU2014208419A1 (enExample)
BR (1) BR112015017650A2 (enExample)
CA (1) CA2898958A1 (enExample)
ES (2) ES2606636T3 (enExample)
HK (1) HK1219753A1 (enExample)
HU (1) HUE032125T2 (enExample)
MX (1) MX2015009323A (enExample)
PL (1) PL2759595T3 (enExample)
RU (1) RU2668794C2 (enExample)
WO (1) WO2014115103A1 (enExample)
ZA (1) ZA201505602B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6208228B2 (ja) 2012-06-21 2017-10-04 ミラゲン セラピューティクス, インコーポレイテッド ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤
EP3247716A4 (en) * 2015-01-20 2018-10-17 Miragen Therapeutics, Inc. Mir-92 inhibitors and uses thereof
WO2018183127A1 (en) * 2017-03-25 2018-10-04 MiRagen Therapeutics, Inc. Mir-92 inhibitors for treatment of heart failure
CN113490488A (zh) * 2019-03-14 2021-10-08 M技术株式会社 Plga微粒子、其缓释制剂以及其制造方法
CN110484537B (zh) * 2019-09-02 2021-07-27 中国水产科学研究院淡水渔业研究中心 一种miR-92促进剂及其注射剂的制备方法和应用
CN110804659B (zh) * 2019-10-23 2023-02-03 华南农业大学 一种血清外泌体ssc-miR-92b-3p作为母猪早期妊娠诊断分子标志物的应用
CN110917359A (zh) * 2019-11-21 2020-03-27 武汉理工大学 离子键自组装制备PEG-P(Asp-AP)-ANTAGOMIR-RNA微球
WO2021251526A1 (ko) * 2020-06-11 2021-12-16 주식회사 프로스테믹스 신규한 mirna 유사체 및 이의 용도
CN111729088B (zh) * 2020-08-21 2020-12-15 江苏申基生物科技有限公司 一种微小核糖核酸miR-34a偶联探针及其制备方法
WO2025050037A1 (en) * 2023-08-31 2025-03-06 The Regents Of The University Of Colorado, A Body Corporate Microrna-15b antagomir and cerium oxide nanoparticles, and uses of same for treatment of intrauterine growth restriction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383158B2 (en) * 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
EP1648914A4 (en) * 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
US8288356B2 (en) * 2007-10-04 2012-10-16 Santaris Pharma A/S MicroRNAs
DE102007052114B4 (de) * 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
GB0814302D0 (en) * 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
CA2763156A1 (en) * 2009-05-20 2010-11-25 Board Of Regents, The University Of Texas System Identification of micro-rnas involved in post-myocardial infarction remodeling and heart failure

Also Published As

Publication number Publication date
ES2606636T3 (es) 2017-03-24
KR20160018451A (ko) 2016-02-17
EP2948551A1 (en) 2015-12-02
MX2015009323A (es) 2016-04-04
CN105229151A (zh) 2016-01-06
BR112015017650A2 (pt) 2017-11-21
HK1219753A1 (zh) 2017-04-13
ZA201505602B (en) 2017-05-31
EP2759595A1 (en) 2014-07-30
WO2014115103A1 (en) 2014-07-31
US20150352055A1 (en) 2015-12-10
HUE032125T2 (en) 2017-08-28
JP2016506923A (ja) 2016-03-07
RU2015134770A (ru) 2017-03-03
RU2668794C2 (ru) 2018-10-02
EP2759595B1 (en) 2016-09-14
ES2688160T3 (es) 2018-10-31
AU2014208419A1 (en) 2015-08-13
EP2948551B1 (en) 2018-05-02
CA2898958A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
PL3065569T3 (pl) Kompozycja
GB201304662D0 (en) Compositions
PT3027750T (pt) Composição biocatalítica
GB201608461D0 (en) Compositions
ZA201505602B (en) Composition comprising an encapsulated antagomir
EP3006525A4 (en) ASPHALT-URETHANE COMPOSITION
GB201318489D0 (en) Composition
GB201319540D0 (en) Composition
GB201320919D0 (en) Composition
GB201317388D0 (en) Composition
GB201320303D0 (en) Composition
GB201319538D0 (en) Composition
GB201306984D0 (en) Composition
SG10201801521QA (en) Anti-obesity composition
GB201322772D0 (en) Composition
GB201317196D0 (en) Composition
IL225985A0 (en) Preparation@cosmetic@mushkollal
GB201307622D0 (en) Composition
PL2767164T3 (pl) Nowe kompozycje
GB201320962D0 (en) Compositions
SG11201602134QA (en) Encapsulation
GB201420672D0 (en) Composition
GB201316082D0 (en) Chitosan composition
GB201308502D0 (en) Composition
GB201301774D0 (en) Composition